ReviewNeoplasia (New York, N.Y.)2013
The role of angiogenesis in human non-Hodgkin lymphomas.
Review in Neoplasia (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 87 citations in OpenAlex.
- Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study.British journal of haematology · 2022Trial
- From CT to Microscopy: Radiological-Histopathological Correlation for Understanding Abdominal Lymphomas.Cancers · 2025Article
- Immune profiling of canine B cell lymphoma reveals cross-species conservation of prognostic markers.Scientific reports · 2025Article
- Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration.Materials today. Bio · 2025Article
- Identification of superficial invasive and indolent lymphomatous lymph nodes by multiple ultrasonographic vascular imaging.Scientific reports · 2025Article
- Gallic Acid Enhances Olaparib-Induced Cell Death and Attenuates Olaparib Resistance in Human Osteosarcoma U2OS Cell Line.Current issues in molecular biology · 2025Article
- In Vivo, In Vitro and In Silico Anticancer Activity of Ilama Leaves: An Edible and Medicinal Plant in Mexico.Molecules (Basel, Switzerland) · 2024Article
- Review
- Non-invasive detection of lymphoma with circulating tumor DNA features and protein tumor markers.Frontiers in oncology · 2024Article
- A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.Clinical and experimental medicine · 2023Article
- Second window indocyanine green localizes CNS lymphoma in real time in the operating room: report of two cases.British journal of neurosurgery · 2023Article
- A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images.Scientific reports · 2023Article
- Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Review
- Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment.Journal of family medicine and primary care · 2022Review
- The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma.BMC cancer · 2022Article
- Immunomodulatory Drugs for the Treatment of B Cell Malignancies.International journal of molecular sciences · 2021Review
- B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.Cancer gene therapy · 2021Article
- Article
- Effect of Tumor Microenvironment and Angiogenesis on Clinical Outcomes of Primary Central Nervous System Lymphoma.BioMed research international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of angiogenesis in the growth of lymphomas and survival of patients with leukemias and other hematological malignancies has become evident since 1994. Angiogenic factors, such as vascular endothelial growth factor and its receptors together with other tumor microenvironment components, including myelo-monocytic cell, mast cells, endothelial progenitor cells, and circulating endothelial cells, have been shown to be important in the progression and maintenance of lymphoproliferative disorders. In this review article, we present an overview of the literature focusing on the relationship between angiogenesis and disease progression and the recent advantages in the antiangiogenic treatment in human non-Hodgkin lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.